These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 24732904

  • 21. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.
    Duvic M, Dummer R, Becker JC, Poulalhon N, Ortiz Romero P, Grazia Bernengo M, Lebbé C, Assaf C, Squier M, Williams D, Marshood M, Tai F, Prince HM.
    Eur J Cancer; 2013 Jan; 49(2):386-94. PubMed ID: 22981498
    [Abstract] [Full Text] [Related]

  • 22. Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides.
    Papadavid E, Antoniou C, Nikolaou V, Siakantaris M, Vassilakopoulos TP, Stratigos A, Stavrianeas N, Katsambas A.
    Am J Clin Dermatol; 2008 Jan; 9(3):169-73. PubMed ID: 18429646
    [Abstract] [Full Text] [Related]

  • 23. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms.
    McGinnis KS, Junkins-Hopkins JM, Crawford G, Shapiro M, Rook AH, Vittorio CC.
    J Am Acad Dermatol; 2004 Mar; 50(3):375-9. PubMed ID: 14988678
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
    Whittaker S, Ortiz P, Dummer R, Ranki A, Hasan B, Meulemans B, Gellrich S, Knobler R, Stadler R, Karrasch M.
    Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
    [Abstract] [Full Text] [Related]

  • 25. CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.
    Gopaluni S, Perzova R, Abbott L, Farah R, Shrimpton A, Hutchison R, Poiesz BJ.
    Am J Hematol; 2008 Sep; 83(9):744-6. PubMed ID: 18615708
    [Abstract] [Full Text] [Related]

  • 26. Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy.
    Brennand S, Sutton VR, Biagi J, Trapani JA, Westerman D, McCormack CJ, Seymour JF, Kennedy G, Prince HM.
    Br J Dermatol; 2005 Jun; 152(6):1199-205. PubMed ID: 15948982
    [Abstract] [Full Text] [Related]

  • 27. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C.
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [Abstract] [Full Text] [Related]

  • 28. Follicular mycosis fungoides: successful treatment with oral bexarotene.
    Shistik G, Scalf LA, Fenske N, Glass LF.
    J Drugs Dermatol; 2004 Feb; 3(3):301-4. PubMed ID: 15176165
    [Abstract] [Full Text] [Related]

  • 29. Sustained remission of treatment-resistant cutaneous T-cell lymphoma with oral bexarotene.
    Mehlmauer MA.
    Cutis; 2004 Jun; 73(6):417-20. PubMed ID: 15224787
    [Abstract] [Full Text] [Related]

  • 30. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
    Scarisbrick JJ, Morris S, Azurdia R, Illidge T, Parry E, Graham-Brown R, Cowan R, Gallop-Evans E, Wachsmuth R, Eagle M, Wierzbicki AS, Soran H, Whittaker S, Wain EM.
    Br J Dermatol; 2013 Jan; 168(1):192-200. PubMed ID: 22963233
    [Abstract] [Full Text] [Related]

  • 31. Oral bexarotene in the treatment of cutaneous T-cell lymphoma.
    Wong SF.
    Ann Pharmacother; 2001 Sep; 35(9):1056-65. PubMed ID: 11573857
    [Abstract] [Full Text] [Related]

  • 32. Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature.
    Quéreux G, Saint-Jean M, Peuvrel L, Brocard A, Knol AC, Dréno B.
    Expert Opin Pharmacother; 2013 Sep; 14(13):1711-21. PubMed ID: 23837676
    [Abstract] [Full Text] [Related]

  • 33. Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations.
    Mehta N, Wayne AS, Kim YH, Hale GA, Alvarado CS, Myskowski P, Jaffe ES, Busam KJ, Pulitzer M, Zwerner J, Horwitz S.
    Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):20-5. PubMed ID: 22001256
    [Abstract] [Full Text] [Related]

  • 34. The optimal use of bexarotene in cutaneous T-cell lymphoma.
    Gniadecki R, Assaf C, Bagot M, Dummer R, Duvic M, Knobler R, Ranki A, Schwandt P, Whittaker S.
    Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
    [Abstract] [Full Text] [Related]

  • 35. [Mycosis fungoid treated with oral bexarotene: study of 13 cases].
    Roche Gamón E, Pérez Ferriols A, Vilata Corell JJ, Alegre de Miquel V.
    Med Clin (Barc); 2007 Nov 10; 129(17):677. PubMed ID: 18005638
    [No Abstract] [Full Text] [Related]

  • 36. Oral bexarotene in a therapy-resistant Sézary syndrome patient: observations on Sézary cell compartmentalization.
    el-Azhary RA, Bouwhuis SA.
    Int J Dermatol; 2005 Jan 10; 44(1):25-8. PubMed ID: 15663654
    [Abstract] [Full Text] [Related]

  • 37. Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene.
    Talpur R, Duvic M.
    Clin Lymphoma Myeloma; 2006 May 10; 6(6):488-92. PubMed ID: 16796781
    [Abstract] [Full Text] [Related]

  • 38. Bexarotene: new preparation. Cutaneous lymphoma: too many adverse effects.
    Prescrire Int; 2004 Jun 10; 13(71):94-7. PubMed ID: 15233146
    [Abstract] [Full Text] [Related]

  • 39. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.
    Singh F, Lebwohl MG.
    J Am Acad Dermatol; 2004 Oct 10; 51(4):570-3. PubMed ID: 15389192
    [Abstract] [Full Text] [Related]

  • 40. Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.
    Talpur R, Thompson A, Gangar P, Duvic M.
    Clin Lymphoma Myeloma Leuk; 2014 Aug 10; 14(4):297-304. PubMed ID: 24589156
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.